Tagged drug-development
Press Release
Elixirgen Scientific Launches Advanced hiPSC-Derived Disease Panel for Alzheimer’s Disease
Maryland-based biotechnology leader, Elixirgen Scientific, Inc., launches Alzheimer’s Disease Panel, strengthening their commitment to quality and innovation in disease research and drug discovery. Read More
Press Release
Incite Health, Inc. Introduces Pharmacogenomics Services to Improve the Safety, Efficacy, and Efficiency of Clinical Trials
New innovative clinical services to help pharmaceutical and biotech companies improve patient recruitment, reduce the risk of adverse reactions, and refine the drug development process. Read More
Press Release
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation. Read More
Press Release
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms Read More
Press Release
PharmaNest to Present Eight Digital Pathology and AI Abstracts at the International Liver Congress 2022
PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest continuous score for the quantification of the severity of fibrosis and treatment effects of NASH therapies at the 2022 International Liver Conference. Read More
Press Release
Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower' Read More
Press Release
PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the AASLD - The Liver Meeting Digital Experience™ (TLMdX) 2021
New digital pathology, quantitative image analysis and quantitative AI method for liver tissues is presented for the continuous assessment of the histological phenotype(s) of fibrosis, including severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid models, NASH rodent models, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021 Read More
Press Release
Woven Science's El Puente Releases Its Policy Paper on Indigenous Reciprocity & Corporate Social Responsibility
Woven Science's El Puente foundation is pleased to release for public comment its policy paper and corporate social responsibility initiative for psychedelic pharmaceutical companies to engage with indigenous peoples using psychedelic botanicals in traditional practice. This paper explores how public policymakers in collaboration with companies can offer indigenous communities influence over product development, consumer preferences, profit sharing, and public perception. Read More
Press Release
GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform
GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain inspired by a family of pepper plants used in traditional medicines around the world. Read More
Press Release
Woven Science Launches Psychedelic Care Platform With Oversubscribed $8.5M Seed Financing
Woven Science is the first company to take a holistic approach to mental wellbeing through psychedelic models of care, while putting a system of reciprocity towards indigenous communities at the core of its business. Read More
Press Release
Glauconix Data Published in Prestigious Ophthalmology Journal as Part of Their Work With NCX 667, a Novel Nitric Oxide Donor Agent With Intraocular Pressure Lowering Ability
The in-vitro studies performed in Glauconix's co-culture 3D conventional human outflow model confirm efficacy Read More
